Market revenue in 2023 | USD 547.1 million |
Market revenue in 2030 | USD 901.1 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 63.3% in 2023. Horizon Databook has segmented the Australia asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The asthma therapeutics market in Australia is anticipated to witness lucrative growth over the forecast period due to the wide distribution network and the geographic expansion of key players in the market. The healthcare systems in Australia have a combination of public and private provisions.
Currently, over 7 million Australians suffer from lung diseases. In Australia, chronic lower respiratory disorders are the fifth largest cause of death. Asthma affects around 2.7 million Australians, or 11% of the population. The government has allocated USD 2 million to increase health practitioner training and education in order to effectively diagnose, manage, & care for individuals with lung diseases.
Through the funding, the Lung Foundation Australia will be able to produce and offer training and education for health professionals to improve the diagnosis, management, and care of people with lung disorders.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account